Previous 10 | Next 10 |
President and CEO David A. Cory resigns from the company effective immediately Dr. David Apelian named Interim CEO Eiger BioPharmaceuticals, Inc. (“Eiger” or “the company”) (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the de...
Rare-disease-focused biotech Eiger BioPharmaceuticals ( NASDAQ: EIGR ) fell 70% pre-market Thursday after announcing topline data from its Phase 3 D-LIVR study for lonafarnib a therapeutic candidate for chronic infections with hepatitis delta virus (HDV). The 407-patient study tri...
Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint PR Newswire - Lonafarnib/ritonavir response rate of 10.1% (p=0.0044) - Lonafarn...
Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022 PR Newswire Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif. ,...
New York, New York--(Newsfile Corp. - November 11, 2022) - Levi & Korsinsky, LLP notifies investors in Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) of a class action securities lawsuit. The lawsuit on behalf of Eiger investors has been commenced in the the Un...
Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire PALO ALTO, Calif. , Nov. 8, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of...
Eiger BioPharmaceuticals, Inc. (EIGR) Q3 2022 Results Conference Call November 03, 2022 04:30 PM ET Company Participants Sarah Mathieson - Senior Vice President, Corporate Affairs David Cory - President and CEO Sri Ryali - Chief Financial Officer Eldon Mayer ...
Eiger BioPharmaceuticals press release ( NASDAQ: EIGR ): Q3 GAAP EPS of -$0.62 misses by $0.10 . Revenue of $4.02M (+32.7% Y/Y) misses by $0.24M . $121.0 million in cash, cash equivalents, and total investments as of September 30, 2022 expected to fund planned ...
Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update PR Newswire Phase 3 HDV D-LIVR (lonafarnib-based regimens) Study Topline Data in December Phase 3 HDV LIMT-2 (peginterferon lambda) Study Activating Sites and...
Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3 PR Newswire - Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif. , Oct. 24, 2022 /PRN...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...